{"brand":"Compound Laws","url":"https://compoundlaws.com/compounds/5-mapb/montana/","compound":{"slug":"5_mapb","name":"5-MAPB","same_as":"https://en.wikipedia.org/wiki/5-MAPB"},"jurisdiction":{"code":"MT","name":"Montana"},"as_of":"2026-10-07","answer":"As of October 7, 2026, 5-MAPB is in a legal gray area (sold in practice, exposed to an interpretive ban theory) in Montana. Analog-exposed (Dangerous Drug Analogue folded into Schedule I; MCA 50-32-222(11)). Controlling source: Mont. Code Ann. 50-32-222 - Specific dangerous drugs included in Schedule I (amphetamine class (4)(nn); dangerous drug analogue entry (11)).","forms":[{"form":"all","label":"All forms","status":"gray","state_status":null,"federal_overlay":false,"headline":"Analog-exposed (Dangerous Drug Analogue folded into Schedule I; MCA 50-32-222(11))","rule_type":"permanent","tier":"analog_exposed","schedule_class":null,"limit":null,"effective_date":"2023-10-01","verified_at":"2026-10-07","confidence":"confirmed","verbatim_excerpt":"50-32-222(11): Dangerous drug analogues. Unless specifically excepted or listed in another schedule, this designation includes any material, compound, mixture, or preparation defined in 50-32-101 as a dangerous drug analogue. 50-32-101(7)(a): Dangerous drug analogue means any material, compound, mixture, or preparation that is structurally related to or chemically derived from any dangerous drug in Schedules I through V ... or that is expressly or impliedly represented to produce or does produce a physiological effect similar to or greater than the effect of a dangerous drug in Schedules I through V.","excerpt_source_url":"https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0220/0500-0320-0020-0220.html","citations":[{"title":"Mont. Code Ann. 50-32-222 - Specific dangerous drugs included in Schedule I (amphetamine class (4)(nn); dangerous drug analogue entry (11))","url":"https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0220/0500-0320-0020-0220.html","pinpoint":null,"publisher":"Montana Legislature (Montana Code Annotated 2025)","type":"legislation","primary":true,"official":true},{"title":"Mont. Code Ann. 50-32-101(7) - Dangerous drug analogue definition","url":"https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0010/section_0010/0500-0320-0010-0010.html","pinpoint":null,"publisher":"Montana Legislature (Montana Code Annotated 2025)","type":"legislation","primary":true,"official":true},{"title":"Mont. Code Ann. 50-32-222(11); 50-32-101(7)","url":"https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0220/0500-0320-0020-0220.html","pinpoint":null,"publisher":null,"type":"statute","primary":true,"official":true}],"history":[]}],"neighbors":[{"code":"ID","status":"legal"},{"code":"ND","status":"illegal"},{"code":"SD","status":"illegal"},{"code":"WY","status":"legal"}],"laws":[{"citation":"MCA 50-32-222(4) (Schedule I hallucinogens — enumerated, 4-HO-MET absent); MCA 50-32-222(11) + 50-32-101(7) (Dangerous Drug Analogue)","title":null,"official_url":"https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0220/0500-0320-0020-0220.html","source_label":"OFFICIAL","effective_date":null,"retrieved_date":"2026-06-19","text_hash":"2aaa76f87ec35feefabb3ab1b57986a40c597b4dd83b03fbe6afba996c638a42"},{"citation":"Mont. Code Ann. 50-32-222(11); 50-32-101(7)","title":"Dangerous drug analogues folded into Schedule I; dangerous drug analogue defined","official_url":"https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0220/0500-0320-0020-0220.html","source_label":"OFFICIAL","effective_date":null,"retrieved_date":"2026-07-20","text_hash":"e7b1283b843566508dac7cbb207e2437135ecc77359570c8187d4320afd3942b"}]}